Related content

Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort

By Haschke-Becher Elisabeth   Kirchheiner Julia   Trummer Olivia   Grünbacher Gerda   Kainz Alexander   Boehm Bernhard O   März Winfried   Renner Wilfried  

Pharmacogenomics, Vol. 11, Iss. 10, 2010-10 ,pp. : 1359-1365

Future Medicine

Access to resources Recommend Favorite

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia   Roots Ivar   Goldammer Mark   Rosenkranz Bernd  

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy

By Seo Takayuki   Nagata Rie   Ishitsu Takateru   Murata Tsukasa   Takaishi Chisato   Hori Masaharu   Nakagawa Kazuko  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 527-537

Future Medicine

Access to resources Recommend Favorite

Impact of genetic polymorphisms of leptin and TNF-α on rosiglitazone response in Chinese patients with type 2 diabetes

By Liu Hai-Ling   Lin Yang-Gen   Wu Jing   Sun Hong   Gong Zhi-Cheng   Hu Ping-Cheng   Yin Ji-Ye   Zhang Wei   Wang Dan   Zhou Hong-Hao   Liu Zhao-Qian  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 7, 2008-07 ,pp. : 663-671

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m‐hydroxymexiletine

By  

Pharmacology Research & Perspectives, Vol. 3, Iss. 5, 2015-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite